ALT-711

DRUG6 trials

Sponsors

Synvista Therapeutics, Inc, Radboud University Medical Center

Conditions

AgingCardiovascular DiseaseChronic Heart FailureDyspneaEndothelial DysfunctionHeart FailureHeart Failure, CongestiveHypertension

Phase 2

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

CompletedNCT00043836

Synvista Therapeutics, IncDyspnea, Heart Failure, Congestive, Pulmonary Edema

Start: 2002-07-31End: 2005-10-31Target: 20Updated: 2009-09-02

The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling

CompletedNCT00045994

Synvista Therapeutics, IncHypertension, Hypertrophy, Left Ventricular

Start: 2001-08-31End: 2003-06-30Target: 180Updated: 2009-07-29

The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)

CompletedNCT00045981

Synvista Therapeutics, IncHypertension

Start: 2001-10-31End: 2006-08-31Target: 450Updated: 2010-03-26

The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure

CompletedNCT00516646

Synvista Therapeutics, IncHeart Failure

Start: 2007-08-31End: 2009-10-31Target: 100Updated: 2010-01-13

Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure

TerminatedNCT00739687

Synvista Therapeutics, IncChronic Heart Failure

Start: 2008-08-31End: 2009-10-31Target: 100Updated: 2009-01-30

Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function

CompletedNCT01417663

Radboud University Medical CenterAging, Cardiovascular Disease, Endothelial Dysfunction +1

Start: 2008-11-30End: 2011-06-30Updated: 2013-09-09

Related Papers

Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

2011-06-1393 citations

Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.

2010-01-2538 citations